May 2, 2024
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Use of proceeds to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit… Read More
learn more
May 2, 2024
Novocure Reports First Quarter 2024 Financial Results
Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR PMA application for TTFields… Read More
learn more
